Navigation Links
Vanda Pharmaceuticals Inc. Presents Scientific Posters at Society for Research on Biological Rhythms (SRBR) Annual Meeting
Date:5/22/2012

report on Form 10-K and quarterly reports on Form 10-Q, other unknown or unpredictable factors also could affect Vanda's results. There can be no assurance that the actual results or developments anticipated by Vanda will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Vanda. Therefore, no assurance can be given that the outcomes stated in such forward-looking statements and estimates will be achieved.

All written and verbal forward-looking statements attributable to Vanda or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein. Vanda cautions investors not to rely too heavily on the forward-looking statements Vanda makes or that are made on its behalf. The information in this release is provided only as of the date of this release, and Vanda undertakes no obligation, and specifically declines any obligation, to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

COMPANY CONTACT: 
Cristina Murphy
Senior Communications Manager
Vanda Pharmaceuticals Inc.
(202) 734-3414
cristina.murphy@vandapharma.com


'/>"/>
SOURCE Vanda Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Vanda Pharmaceuticals Reports First Quarter 2012 Results
2. Vanda Pharmaceuticals to Participate in Upcoming Investor Conferences
3. Vanda Pharmaceuticals Reports Fourth Quarter 2011 and Full Year 2011 Results
4. Vanda Pharmaceuticals Enters into an Exclusive License Agreement with Megapharm Ltd. for Commercialization of Fanapt™ in Israel
5. Vanda Pharmaceuticals Reports Third Quarter 2011 Results
6. Vanda Pharmaceuticals Appoints Chief Commercial Officer
7. Vanda Pharmaceuticals to Participate in UBS Global Life Sciences Conference
8. Vanda Pharmaceuticals to Participate in Stifel Nicolaus Global Healthcare Conference and Jefferies Fall 2011 Mid-Atlantic Corporate Access Day
9. Vanda Pharmaceuticals Reports Second Quarter 2011 Results
10. Vanda Pharmaceuticals to Announce Second Quarter 2011 Financial Results on August 4, 2011
11. Vanda Pharmaceuticals Enters into an Exclusive License Agreement with Probiomed S.A. de C.V. for Commercialization of Fanapt™ in Mexico
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... , June 19, 2013   Voices Against ... finding a cure for brain cancer, today announced that ... grant to support the clinical investigation of Toca 511 ... high grade glioma brain cancer (Grade 3 or Grade ... novel treatments for advanced cancer, with an initial focus ...
(Date:6/19/2013)... DIEGO , June 19, 2013   Nektar Therapeutics ... results from a human abuse liability (HAL) study for ... rate of entry into the brain.  This slow rate of ... to the abuse of and addiction to current opioid analgesics. ... NKTR-181 was rated similar to placebo in "drug liking" ...
(Date:6/19/2013)... , June 19, 2013 NeuroDerm, ... study in volunteers, and preliminary results from a phase ... presented at the 2013 International Congress of Parkinson,s Disease ... drug formula under development for continuous administration through a ... plasma concentrations. ND0612 has been shown in ...
Breaking Medicine Technology:Voices Against Brain Cancer Awards Grant to Tocagen to Support Investigation of Toca 511 & Toca FC in Patients with Recurrent Brain Cancer 2Voices Against Brain Cancer Awards Grant to Tocagen to Support Investigation of Toca 511 & Toca FC in Patients with Recurrent Brain Cancer 3Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 2Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 3Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 4Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 5Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 6Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 7Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 8Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 9NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 2NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 3NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 4NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 5NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 6
... Varian Medical Systems (NYSE: VAR ) ... U.S. Customs and Border Protection (CBP) for multiple IntellX® cargo ... company,s largest single order for Varian,s IntellX gantry systems. The ... vehicles for both border security and manifest verification purposes. ...
... 2011 DURECT Corporation (Nasdaq: DRRX ) ... (FDA) has accepted the resubmission of the New Drug ... KG ) and the PDUFA goal date ... ) REMOXY, based on DURECT,s ORADUR® technology, ...
Cached Medicine Technology:Varian Medical Systems' Security and Inspection Products Group Receives Largest Single Order for IntellX Systems 2REMOXY® New Drug Application Accepted by the FDA with PDUFA Goal Date of June 23, 2011 2REMOXY® New Drug Application Accepted by the FDA with PDUFA Goal Date of June 23, 2011 3
(Date:6/19/2013)... along with the Japanese government and the Bill ... bolster Japan,s contribution to global health through the ... a press conference held as a side event ... Development (TICAD V). , Representatives from each of ... Labour and Welfare, the Ministry of Foreign Affairs, ...
(Date:6/19/2013)... Dental professionals are increasingly monitoring end tidal carbon ... sedation, a patient’s breathing depth and rate decrease. ... to update its guidelines to require etCO2 monitoring, or ... to increase safety in procedures. This amendment to Section ... effect July 1. , The Oregon Board of ...
(Date:6/19/2013)... Ariz. (PRWEB) June 19, 2013 PREFERRED ... WellCare of Arizona to offer a new ... Maricopa, Pima, La Paz, Yavapai and Mohave, Arizona counties. ... Mohave counties were effective January 1, 2013 and Maricopa ... 2014. , WellCare, Inc., the parent company of WellCare ...
(Date:6/19/2013)... Brightree LLC , the leading provider of cloud-based ... care industry, has been ranked for the first time - ... (HCI 100) list. This prestigious list features the top ... revenue during the last fiscal year. Since 2005, Brightree’s revenue ... the company has built its organization to more than 500 ...
(Date:6/19/2013)... Guests at the Residence Inn Scottsdale Paradise Valley ... go to bed or rise early thanks to a new ... , Crafty travelers will have a little extra change in ... Paradise Valley hotel’s Book Early and Save Up to ... notice, guests can enjoy the year-round Scottsdale sunshine in deluxe ...
Breaking Medicine News(10 mins):Health News:GHIT Fund celebrates historic beginning of Japanese R&D initiative in global health 2Health News:GHIT Fund celebrates historic beginning of Japanese R&D initiative in global health 3Health News:Required Capnography Monitoring Growing Trend Among National and State Healthcare Organizations 2Health News:Required Capnography Monitoring Growing Trend Among National and State Healthcare Organizations 3Health News:PREFERRED Therapy Providers, Inc. and WellCare of Arizona Finalize Their Agreement to Offer Medicare Advantage Plan to PREFERRED's Arizona Provider Network 2Health News:Brightree Debuts on List of Top 100 Healthcare Technology Companies 2Health News:Brightree Debuts on List of Top 100 Healthcare Technology Companies 3Health News:Plan Ahead and Save Big With New Deal From Residence Inn Scottsdale Paradise Valley 2Health News:Plan Ahead and Save Big With New Deal From Residence Inn Scottsdale Paradise Valley 3Health News:Plan Ahead and Save Big With New Deal From Residence Inn Scottsdale Paradise Valley 4
... of the BBVA Foundation, Francisco Gonzlez, Jose Baselga, ... Center (MGHCC), and Andrs de Kelety, Managing Director ... in Barcelona, yesterday signed the agreement creating the ... the event was the Foundation,s Director, Mr. Rafael ...
... (HealthDay News) -- Women and younger men account for a ... are less likely than older men to receive preventive medications ... Researchers evaluated more than 3,000 heart attack patients treated at ... and found that 70.3 percent of them had not been ...
... study to investigate the tolerability of the breast cancer drug ... stop taking their prescribed therapy early because of problems with ... of the research paper, published today in the cancer journal ... 64 male breast cancer patients at their institution who had ...
... rely on recombinant, protein-based drugs must often endure ... intravenous therapy. Researchers at Children,s Hospital Boston demonstrate ... engineered cells, could secrete the drug on demand ... issue of the journal Blood , they ...
... By Randy Dotinga HealthDay Reporter , TUESDAY, ... whole-body vibration doesn,t appear to improve the bone health ... osteoporosis. The treatment -- which involves standing on a ... -- showed promise in animals. But researchers, who hoped those ...
... read will be one of the topics of a conference ... co-sponsored by the UC Davis Center for Mind and Brain, ... Visual Learning, and the departments of psychology and linguistics at ... to read, said David Corina, professor in the Department of ...
Cached Medicine News:Health News:Mass. General Cancer Center and Vall d'Hebron Institute of Oncology biomarker alliance 2Health News:Mass. General Cancer Center and Vall d'Hebron Institute of Oncology biomarker alliance 3Health News:Women, Younger Men Under-Treated Before Heart Attack: Study 2Health News:Male breast cancer patients stop taking tamoxifen early because of drug-related side effects 2Health News:Male breast cancer patients stop taking tamoxifen early because of drug-related side effects 3Health News:Engineered, drug-secreting blood vessels reverse anemia in mice 2Health News:Engineered, drug-secreting blood vessels reverse anemia in mice 3Health News:Whole-Body Vibration Doesn't Build Bone After All: Study 2Health News:Visual language, cognition and deaf education topics of summit 2
... the right features for assay development ... instrument control. Reduces the inevitable transfer ... HTS. Specifically developed to meet the ... AD delivers unparalleled detection performance for ...
... The POLARstar OPTIMA is a fully ... incorporates five different measurement principles:, , ... , Time-Resolved Fluorescence , High-Performance ... Absorbance ,It is designed ...
... of PCR, cDNA and Oligonucleotides The ... for a variety applications that are quantified by ... to handle assays in Microplate formats from ... Cuvettes Independent whether you have ...
The basic modular Wallac 1420 VICTOR2 is a manually operated platereader which enables luminometry, fluorometry and photometry measurements to be made....
Medicine Products: